AP NEWS

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - 2018 Pipeline Insights - ResearchAndMarkets.com

December 17, 2018

DUBLIN--(BUSINESS WIRE)--Dec 17, 2018--The “Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report offers comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection pipeline products by developmental stage, product type, molecule type, and administration route.

Key Topics Covered

1. Report Introduction

2. Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name : Company Name

Product Description Research and Development Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name : Company Name

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment

Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name : Company Name

Product Description Research and Development Product Development Activities

Companies Featured

Atriva Therapeutics GmbH Autoimmune Technologies LLC CEL-SCI Corp. Fab’entech S.A. GeneCure LLC Nanotherapeutics Inc. Novavax Inc. Oncovir Inc. Phelix Therapeutics LLC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/6dw954/severe_acute?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181217005436/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs,Infectious Diseases Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/17/2018 09:31 AM/DISC: 12/17/2018 09:31 AM

http://www.businesswire.com/news/home/20181217005436/en

AP RADIO
Update hourly